TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00631085

Intervention type: DRUG
Group type: OTHER
Intervention: gamma tocopherol
Description: Maxi Gamma softgels 1200mg QD
Study: NCT02068170

Intervention type: DRUG
Intervention: Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
Study: NCT04481893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a virtual reality headset
Description: The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~* The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~* The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)
Study: NCT00386425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: intravenous
Study: NCT01270386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib 750 mg p.o. once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo p.o. once daily
Study: NCT03914027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home.
Study: NCT00112021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Study: NCT02554318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented soybean
Study: NCT01099774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% Formulation B Ophthalmic Solution
Description: One drop administered in each eye, every evening, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.03% Ophthalmic Solution
Description: One drop administered in each eye, every evening, for 12 weeks
Study: NCT00854919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atypical antipsychotic drug
Description: For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atypical antipsychotic drug
Description: For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure response prevention
Description: After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure response prevention
Description: After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure response prevention
Description: After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
Study: NCT00033657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
Study: NCT02315872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: ACTH injections twice weekly for 28 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections twice weekly for 28 weeks.
Study: NCT04003454

Intervention type: OTHER
Group type: OTHER
Intervention: HCV Screening
Description: The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.

Intervention type: OTHER
Group type: OTHER
Intervention: HCV Screening
Description: The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
Study: NCT03434249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium, BB-12® (Bifidolactis Infant)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidolactis Infant Placebo
Study: NCT04647656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
Study: NCT02660606

Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)

Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)

Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)

Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)
Study: NCT04713436

Intervention type: DRUG
Intervention: Differentiation Markers
Description: Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Intervention type: DRUG
Intervention: Differentiation Markers
Description: Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Intervention type: DRUG
Intervention: Differentiation Markers
Description: Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
Study: NCT00672399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
Study: NCT02340611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
Study: NCT02258542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously
Study: NCT00526331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigileo Monitor
Description: Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigileo Monitor
Description: Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac Sensor
Description: Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac Sensor
Description: Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
Study: NCT04407429

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Analyses
Description: Storage of serum for SARS-CoV-2-antibodies and biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Analyses
Description: Storage of serum for SARS-CoV-2-antibodies and biomarkers
Study: NCT02432859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Direct current with sensory intensity for one hour

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Direct current with zero intensity for one hour
Study: NCT01916161

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT03816644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Cog
Description: The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Literacy & Grip Assessment
Description: The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
Study: NCT01897610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
Study: NCT05590806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct composite build-ups
Description: Direct composite build-ups application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct composite build-ups
Description: Direct composite build-ups application
Study: NCT01878734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders
Description: Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
Study: NCT03774225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality with Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with No Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
Study: NCT03973047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: Sterile aqueous solution for injection, provided as an autoinjector pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bremelanotide
Description: Sterile aqueous solution for injection, provided as an autoinjector pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: 8 mg tablet (over-encapsulation in a capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study: NCT03774225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with No Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality with No Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients of the control group will be trained with balance exercises by a experient physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients of the control group will be trained with balance exercises by a experient physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group will be trained with balance exercises by a experient physiotherapist.
Study: NCT03259672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane was used as a maintenance anesthetic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane was used as a maintenance anesthetic agent.
Study: NCT02262598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide (HCTZ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ fixed dose
Study: NCT03907930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotripsy
Description: removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotripsy
Description: removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
Study: NCT03412188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment